Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

NCT05378529 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: * Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD * Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions

Interventions

  • OTHER Lp(a) Screening

Study Locations (20)

California

  • Care Access - Berkeley — Berkeley
  • National Heart Institute — Beverly Hills
  • NorCal Medical Research, Inc — Greenbrae
  • America Clinical Trials — Tarzana
  • Med Partners, Inc dba Premiere Medical Center, Inc — Toluca Lake

Florida

  • Excel Medical Clinical Trials — Boca Raton
  • Bay Area Cardiology — Brandon
  • Clearwater Cardiovascular Consultants — Clearwater
  • Cardiology Associates Research LLC — Daytona Beach
  • The Cardiac and Vascular Institute Research — Gainesville

Alabama

  • Ascension Saint Vincents Birmingham — Birmingham
  • Grandview Medical Center Affinity Cardiovascular Specialists, LLC — Birmingham
  • Heart Center Research LLC — Huntsville
  • Mobile Heart Specialists PC — Mobile

Arizona

  • Care Access - Mesa — Mesa
  • Elite Clinical Studies LLC — Phoenix

Alaska

  • Alaska Cardiovascular Research Foundation — Anchorage

Arkansas

  • Arkansas Cardiology — Little Rock

Colorado

  • UCHealth Memorial Central — Colorado Springs

Connecticut

  • Cardiology Associates of Fairfield County PC — Stamford

Trial Details

FieldValue
Enrollment Target 39,480 participants
Start Date 2022-04-19
Est. Completion 2023-12-30
Phase NA

Sponsor

Amgen

266 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05378529

The ClinicalTrials.gov registry entry for NCT05378529 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 39,480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 266 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention — of which Lp(a) Screening is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05378529 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05378529 about?

NCT05378529 is a clinical study titled "A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)". The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: * Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD * Eval...

What is the current status of trial NCT05378529?

This trial is currently completed. It is a NA study. The enrollment target is 39,480 participants. The study started on 2022-04-19. Estimated completion is 2023-12-30.

What conditions does trial NCT05378529 study?

This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05378529?

The interventions under investigation include: Lp(a) Screening (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05378529?

This trial is sponsored by Amgen, which has 266 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05378529 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial